Seminars in Oncology
Volume 33, Issue 6 , Pages 664-671 , December 2006

Preservation of Fertility and the Impact of Subsequent Pregnancy in Patients With Premenopausal Breast Cancer

  • Meyeon Park

      Affiliations

    • University of Pennsylvania, Philadelphia, PA.
    • ,
  • Rebecca Davidson

      Affiliations

    • Department of Medicine, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA.
    • ,
  • Kevin Fox

      Affiliations

    • Department of Medicine, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA.
    • Corresponding Author InformationAddress correspondence to Kevin Fox, MD, Medical Director, Rena Rowan Breast Center, 14 Penn Tower, Philadelphia, PA 19104.

References 

  1. Hankey BF, Miller B, Curtis R, et al. Trends in breast cancer in younger women in contrast to older women. J Natl Cancer Inst Monogr. 1994;16:7–14
  2. Higgins S, Haffty BG. Pregnancy and lactation after breast-conserving therapy for early stage breast cancer. Cancer. 1994;73:2175–2180
  3. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718–1729
  4. Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365–2370
  5. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5
  6. Partridge AH, Winer EP. Fertility after breast cancer: questions abound. J Clin Oncol. 2005;23:4259–4261
  7. Hortobagyi GN. Progress is systemic chemotherapy of primary breast cancer: An overview. J Natl Cancer Inst Monogr. 2001;30:72-70
  8. Poniatowski BC, Grimm P, Cohen G. Chemotherapy-induced menopause: A literature review. Cancer Invest. 2001;19:641–648
  9. Shapiro C, Henderson C. Adjuvant therapy of breast cancer. In:  Shapiro C,  Henderon I editor. Hematology/Oncology Clinics of North America New Directions in Breast Cancer Research and Therapeutics. Philadelphia, PA: Saunders; 1994;p. 213–230
  10. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet. 1998;351:1451–1467
  11. Jonat W, Kaufmann M, Wauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex early breast cancer research association study. J Clin Oncol. 2002;20:4628–4635
  12. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Human Reprod Update. 2001;7:535–543
  13. Ataya K, Mognissi K. Chemotherapy-induced ovarian failure: Mechanisms and prevention. Steroids. 1989;54:607–626
  14. Meyn R, Murray D. Cell cycle effects of alkylating agents. In:  Dethlefsen L editors. Cell Cycle Effects of Drugs. (ed 1). New York, NY: Pergamon; 1986;p. 179
  15. Pydyn E, Ataya K. Effect of cyclophosphamide on mouse oocytes in vitro fertilization and cleavage recovery. Reprod Toxicol. 1991;5:73–78
  16. Sonmezer M, Oktay K. Fertility preservation in female patients. Human Reprod Update. 2004;10:251–266
  17. Fisher B, Cheung AY. Delayed effect of radiation therapy with or without chemotherapy on ovarian function in women with Hodgkin’s disease. Acta Radiol Oncol. 1984;23:43–48
  18. Sanders JE, Hawley J, Levy W, et al. Pregnancies following high dose cyclophosphamide with or without high dose busulfan or total body irradiation and bone marrow transplant. Blood. 1996;87:3045–3052
  19. Moore HC. Following treatment for breast cancer (The incidence of treatment-related amenorrhea is related to patient age and to the treatment regimen). Curr Oncol Rep. 2000;2:587–593
  20. Thewes B, Meiser B, Duric V, et al. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?. Lancet Oncol. 2005;6:581–588
  21. International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trail. J Natl Cancer Inst. 2003;95:1833–1846
  22. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431–2442
  23. Dellapasqua S, Colleoni M, Gelber RD, et al. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol. 2005;23:1736–1750
  24. Meirow D, Lewis H, Nugent D, et al. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: Clinical importance and proposed accurate investigative tool. Hum Reprod. 1999;14:1902–1907
  25. Lower EE, Blau R, Gazder P, et al. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med. 1999;8:939–954
  26. Reyno LM, Levine MN, Skingley P, et al. Chemotherapy induced amenorrhea in a randomized trial of adjuvant chemotherapy duration in breast cancer. Eur J Cancer. 1993;29A:21–23
  27. Byrne J, Fears TR, Gail MH, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol. 1992;166:788–793
  28. Wallace WH, Shalet SM, Tetlow LJ, et al. Ovarian function following the treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1993;21:333–339
  29. Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada (AM J). Epidemiol. 1999;150:245–254
  30. Sutton R, Buzdar AJ, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer. 1990;65:847–850
  31. Burstein HJ, Winer EP. Reproductive issues. In:  Harris JR editors. Diseases of the Breast. (ed 2). Philadelphia, PA: Lippincott Williams & Wilkins; 2000;
  32. Kramer R, Tham Y, Sexton K, et al. Chemotherapy-induced amenorrhea is increased in patients treated with adjuvant doxorubicin and cyclophosphamide (AC) followed by a taxane (T). Proc Am Soc Clin Oncol. 2005;23:41s;(abstr)
  33. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol. 2000;169:123–131
  34. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001;19:3306–3311
  35. Lobo RA. Potential Options for preservation of fertility in women. N Engl J Med. 2005;353:64–73
  36. Rebar RW. Premature ovarian failure. In:  Lobo RA,  Kelsey J,  Marcus R editor. Menopause: Biology and Pathobiology. San Diego, CA: Academic Press; 2000;p. 135–146
  37. Letur H, Martin-Pont B, Fenichel P. Spontaneous pregnancies and premature menopause. Gynecol Obstet Fertil. 2004;32:748–755
  38. Larsen EC, Muller J, Rechnitzer C, et al. Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH <10 IU/l. Hum Reprod. 2003;18:417–422
  39. Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin’s disease. Med Pediatr Oncol. 1996;27:74–78
  40. Schilsky RL, Sherins RJ, Hubbard SM, et al. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin’s disease. Am J Med. 1981;71:552–556
  41. Clark ST, Redford JA, Crowther D, et al. Gonadal function following chemotherapy for Hodgkin’s disease: A comparative study of MVP and a seven-drug hybrid regimen. J Clin Oncol. 1995;13:134–139
  42. Oktay K, Buyuk E, Davis O, et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Human Reprod. 2003;18:90–95
  43. Oktay K, Karlikaya M. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N Engl J Med. 2000;342:1919
  44. Oktay K, Economos K, Kan M, et al. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA. 2001;236:1490–1493
  45. Oktay K, Buyuk E. The potential of ovarian tissue transplant to preserve fertility. Expert Opin Biol Ther. 2002;2:361–370
  46. Morita Y, Perez GI, Paris F, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med. 2000;6:1109–1114
  47. 2002 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports. Atlanta, GA, Centers for Disease Control and Prevention, December 2004. http://www.cdc.gov/reproductivehealth/ART02/PDF/ART2002.pdf (accessed June 13, 2005)
  48. Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23:1–7
  49. Omland AK, Fedorcsak P, Storeng R, et al. Natural cycle IVF in unexplained, endometriosis-associated and tubal factor infertility. Hum Reprod. 2001;16:2587–2592
  50. Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol. 2005;23:3858–3859
  51. Crosignani PG, Bianchedi D, Riccaboni A, et al. Management of anovulatory infertility. Hum Reprod. 1999;14(suppl 1):108–119
  52. Shushan A, Peretz T, Mor-Yosef S. Therapeutic approach to ovarian cysts in tamoxifen-treated women with breast cancer. Int J Gynaecol Obstet. 1996;52:249–253
  53. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–1802
  54. Oktay K, Kan MT, Rosenwaks Z. Recent progress in oocytes and ovarian tissue cryopreservation and transplantation. Curr Opin Obstet Gynecol. 2001;13:263–268
  55. Fabbri R, Porcu E, Marsella T, et al. Human oocyte cryopreservation: New perspectives regarding oocyte survival. Hum Reprod. 2001;16:411–416
  56. The Practice Committee of the American Society for Reproductive Medicine. Ovarian tissue and oocytes cryopreservation. Fertil Steril. 2004;82:993–998
  57. Oktay K, Aydin BA, Karlikaya G. A technique for laparoscopic transplantation of frozen-banked ovarian tissue. Fertil Steril. 2001;75:1212–1216
  58. Oktay K, Economos K, Kan M, et al. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA. 2001;286:1490–1493
  59. Oktay K, Buyuk E, Veeck L, et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;363:837–840
  60. Gosden RG, Baird DT, Wade JC, et al. Restoration of fertility to oophorectomized sheep by ovarian autografts stored at -196 degrees C. Hum Reprod. 1994;9:597–603
  61. Sztein J, Sweet H, Farley J, et al. Cryopreservation and orthotopic transplantation of mouse ovaries: New approach in gamete banking. Biol Reprod. 1998;58:1071–1074
  62. Liu J, Van der Elst J, Van den Broecke R, et al. Live offspring by in vitro fertilization of oocytes from cryopreserved primordial mouse follicles after sequential in vivo transplantation and in vitro maturation. Biol Reprod. 2001;64:171–178
  63. Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 1988;259:2123–2125
  64. Meirow D, Assad G, Dor J, et al. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Human Reprod. 2004;19:1294–1299
  65. Couzinet B, Lahlou N, Thomas G, et al. Effects of gonadotrophin releasing hormone antagonist and agonist on the pulsatile release of gonadotrophins and alpha-subunit in postmenopausal women. Clin Endocrinol. 1991;34:477–483
  66. Matikainen T, Ding YQ, Vergara M, et al. Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women. J Clin Endocrinol Metab. 1992;75:820–825
  67. Rabinovici J, Rothman P, Monroe SE, et al. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-rleasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: Studies in postmenopausal women. J Clin Endocrinol Metab. 1992;75:1220–1225
  68. Blumenfeld Z, Avivi I, Linn S, et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod. 1996;11:1620–1626
  69. Fox K, Scialla J, Moore H. Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer. Proc Am Soc Clin Oncol. 2003;22:13;(abstr)
  70. Recchia F, Saggio G, Amiconi G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer. 2006;106:514–523
  71. DelMastro L, Catzeddu T, Boni L. Temporary ovarian suppression with goserelin for prevention of chemotherapy-induced menopause in young early breast cancer patients: Results of a phase II study. Proc Am Soc Clin Oncol. 2005;23:44s;(abstr)
  72. Jeremias E, Bedaiwy MA, Gurunluoglu R, et al. Heterotopic autotransplantation of the ovary with microvascular anastomosis: A novel surgical technique. Fertil Steril. 2002;77:1278–1282
  73. Wang X, Chen H, Yin H, et al. Fertility after intact ovary transplantation. Nature. 2002;415:385
  74. Bedaiwy MA, Jeremias E, Gurunluoglu R, et al. Restoration of ovarian function after autotransplantation of intact frozen-thawed sheep ovaries with microvascular anastomosis. Fertil Steril. 2003;79:594–602
  75. Chiu DT, Hu G. Evaluation of the hormonal function and histological features of heterotopic isogenic ovarian transplantation in rats. Plast Reconstr Surg. 2003;111:1646–1652
  76. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–2846
  77. Buzdar AU, Smith TL, Blumenschien GR, et al. Breast cancer adjuvant therapy trials of M.D. Anderson Hospital: Results of two studies. In:  Jones SE,  Salmon SE editor. Adjuvant Therapy of Cancer IV. Orlando, FL: Grune & Stratton; 1984;p. 217–225
  78. Danforth DN. How subsequent pregnancy affects outcome in women with a prior breast cancer. Oncology. 1991;5:23–30
  79. Gelber S, Coates AS, Goldhirsch A, et al. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol. 2001;19:1671–1675
  80. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: healthy mother effect. Am J Obstet Gynecol. 1994;170:818–823
  81. Blakely LJ, Buzdar AU, Lozada JA, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer. 2004;200:465–469
  82. Velentgas P, Daling JR, Malone KE, et al. Pregnancy after breast carcinoma: Outcomes and influence on mortality. Cancer. 1999;85:2424–2432
  83. Kroman N, Jensen MB, Melbye M, et al. Should women be advised against pregnancy after breast-cancer treatment?. Lancet. 1997;350:319–322
  84. von Schoultz E, Johansson H, Wilking N, et al. Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol. 1995;13:430–434
  85. Malamos NA, Stathopoulos GP, Keramopoulos A, et al. Pregnancy and offspring after the appearance of breast cancer. Oncology. 1996;53:471–475
  86. Ariel IM, Kempner R. The prognosis of patients who become pregnant after mastectomy for breast cancer. Int Surg. 1989;74:185–187
  87. Petrek JA, Theriault RL. Pregnancy-associated breast cancer and subsequent pregnancy in breast cancer survivors. In:  Harris JR,  Lippman ME,  Morrow M, et al. editor. Diseases of the Breast. Philadelphia, PA: Lippincott; 2004;p. 1035–1046
  88. Blatt J, Mulvihill JJ, Zeigler JL, et al. Pregnancy outcome following cancer chemotherapy. Am J Med. 1980;69:828–832
  89. Mulvihill JJ, McKeen EA, Rosner F, et al. Pregnancy outcome in cancer patients (Experience in a large cooperative group). Cancer. 1987;60:1143–1150
  90. Johnson P, Gwyn K, Gordon N, et al. The treatment of pregnant women with breast cancer and the outcomes of children exposed to chemotherapy in utero. Proc Am Soc Clin Oncol. 2005;23:13s;(abstr)

PII: S0093-7754(06)00326-5

doi: 10.1053/j.seminoncol.2006.08.015

Seminars in Oncology
Volume 33, Issue 6 , Pages 664-671 , December 2006

Article Tools